A Randomized, Double-blind, Placebo-controlled Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Study of Administrating Single Ascending Dose of HMS5552 in Healthy Adult Volunteers

Trial Profile

A Randomized, Double-blind, Placebo-controlled Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Study of Administrating Single Ascending Dose of HMS5552 in Healthy Adult Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jun 2015

At a glance

  • Drugs Sinogliatin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Hua Medicine
  • Most Recent Events

    • 09 Jun 2015 Results of pooled analysis of two phase I trials presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
    • 19 Mar 2014 Results were reported in a Hua Medicine media release.
    • 19 Mar 2014 Results will be presented at the American Diabetes Association Conference according to a Hua Medicine media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top